Main Menu

Our Work

Sartorius Stedim Biotech acquisition of Novasep chromatography business

On behalf of Sartorius Stedim Biotech, Nicholas Hill provided expert analysis of its proposed acquisition of the chromatography business of Novasep Process SAS. Novasep’s chromatography equipment division primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides, and insulin. Novasep and Sartorius had collaborated on the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively. Dr. Hill provided presentations to the Federal Trade Commission, which determined the transaction was unlikely to substantially lessen competition in the relevant market and approved the acquisition.

More information is available here

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.